PriceTargets.com logo

ImmunityBio - IBRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.80
  • Forecasted Upside: 88.80%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$6.25 As of 01/30/2026 05:00 PM ET
▲ +0.34 (5.75%)

This chart shows the closing price for IBRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImmunityBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IBRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IBRX

Analyst Price Target is $11.80
▲ +88.80% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for ImmunityBio in the last 3 months. The average price target is $11.80, with a high forecast of $24.00 and a low forecast of $7.00. The average price target represents a 88.80% upside from the last price of $6.25.

This chart shows the closing price for IBRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in ImmunityBio. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/26/2026HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $10.00
1/22/2026BTIG ResearchBoost TargetBuy ➝ Buy$6.00 ➝ $9.00
1/20/2026Piper SandlerBoost TargetOverweight ➝ Overweight$5.00 ➝ $7.00
1/20/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$24.00
1/13/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$24.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/12/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$8.00 ➝ $9.00
12/11/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$24.00
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/13/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$24.00
11/5/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/5/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$24.00
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00
9/8/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$24.00
8/26/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$24.00
8/14/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$24.00
8/5/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
7/25/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
7/8/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
6/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00
6/3/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
5/28/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00
5/20/2025Piper SandlerUpgradeNeutral ➝ Overweight$4.25 ➝ $5.00
5/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/12/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/5/2025HC WainwrightReiterated RatingBuy ➝ Buy
4/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/23/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
4/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/15/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
4/9/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/31/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
3/13/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/6/2025HC WainwrightInitiated CoverageBuy$8.00
2/28/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
2/14/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
1/27/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
1/16/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
1/10/2025BTIG ResearchInitiated CoverageBuy$6.00
1/6/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
12/20/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
11/21/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/23/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
8/19/2024Piper SandlerLower TargetNeutral ➝ Neutral$6.00 ➝ $4.75
4/29/2024Piper SandlerBoost TargetNeutral ➝ Neutral$5.00 ➝ $6.00
3/25/2024Piper SandlerBoost TargetNeutral ➝ Neutral$4.00 ➝ $5.00
5/12/2023Piper SandlerDowngradeOverweight ➝ Neutral$10.00 ➝ $4.00
8/3/2022Jefferies Financial GroupInitiated CoverageBuy$8.00
5/27/2022Piper SandlerLower Target$20.00 ➝ $10.00
4/7/2021Piper SandlerBoost TargetOverweight$18.00 ➝ $25.00
(Data available from 2/1/2021 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
7/6/2025
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/5/2025
  • 10 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2025
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2025
  • 8 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 8 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
1/2/2026
  • 34 very positive mentions
  • 43 positive mentions
  • 9 negative mentions
  • 1 very negative mentions
Mentions as of
2/1/2026

Current Sentiment

  • 34 very positive mentions
  • 43 positive mentions
  • 9 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

ImmunityBio logo
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Read More

Today's Range

Now: $6.25
Low: $5.67
High: $6.47

50 Day Range

MA: $3.14
Low: $1.98
High: $7.34

52 Week Range

Now: $6.25
Low: $1.83
High: $8.28

Volume

29,300,913 shs

Average Volume

51,653,440 shs

Market Capitalization

$6.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunityBio?

The following Wall Street sell-side analysts have issued reports on ImmunityBio in the last twelve months: BTIG Research, D. Boral Capital, HC Wainwright, Jefferies Financial Group Inc., Piper Sandler, and Weiss Ratings.
View the latest analyst ratings for IBRX.

What is the current price target for ImmunityBio?

0 Wall Street analysts have set twelve-month price targets for ImmunityBio in the last year. Their average twelve-month price target is $11.80, suggesting a possible upside of 88.8%. D. Boral Capital has the highest price target set, predicting IBRX will reach $24.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $7.00 for ImmunityBio in the next year.
View the latest price targets for IBRX.

What is the current consensus analyst rating for ImmunityBio?

ImmunityBio currently has 1 sell rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IBRX.

What other companies compete with ImmunityBio?

Other companies that are similar to ImmunityBio include Genmab A/S, Revolution Medicines, Moderna, Roivant Sciences and Viatris. Learn More about companies similar to ImmunityBio.

How do I contact ImmunityBio's investor relations team?

ImmunityBio's physical mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The company's listed phone number is (858) 633-0300 and its investor relations email address is [email protected]. The official website for ImmunityBio is immunitybio.com. Learn More about contacing ImmunityBio investor relations.